Cephalosporin Market Report 2021

Home   /   Cephalosporin Market Report 2021

Published Date: August 2021 | Pages: 144 | Category: Pharma and Healthcare | Report Code: GRMI70106

Extract:

 

The Cephalosporin market is said to witness a significant growth during the forecast years between 2021 and 2028. Cephalosporin is a broad-spectrum, -lactam antibiotic derived from the fungus Acremonium that is used to treat bacterial infections such as pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, gonorrhoea, and others. They inhibit enzymes in the cell walls of susceptible bacteria, causing cell synthesis to be disrupted. Cephalosporins are primarily used in the prevention and treatment of bacterial infections. First-generation cephalosporins primarily inhibit the growth of gram-positive bacteria such as Streptococcus and Staphylococcus.

 

Report Scope in detail:

 

This latest report edition of Cephalosporin market has been added to our huge database of detailed reports and this envisions to shape the future of all the related businesses. Our team of learned research analysts have studied in-depth and curated the report based on several aspects which include the overview of the market, driving forces, growth rate, market trends, market size, opportunities and challenges of the market; along with detailed competitive analysis on the regional as well as global level. The Cephalosporin market research report renders a thorough analysis of the market on a global aspect and aims on several market segmentation. This report also provides deeper perception into the latest trends of the market and pinpoints crucial product developments of the industry. Furthermore, the report collects numerous factors that have accredited to the growth of the market in the recent years.

 

Market Dynamics:

 

  • The global cephalosporin market is expanding due to an increase in the prevalence of infectious diseases, an increase in R&D activities for the development of combination drugs, and an increase in funding for antibiotic development.
  • Furthermore, the rise in demand for antibacterial drugs propels the global cephalosporin market forward.
  • Cephalosporin side effects, uncertain regulatory reforms, and fewer drugs in the pipeline are expected to stymie cephalosporin market growth.
  • Market participants are expected to benefit from the discovery of advanced prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant microbial infections.

 

Cephalosporin Market Segmentation:

 

By Type

  • Generic
  • Branded

 

By Generation

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin

 

By Application

  • Skin Infection
  • Respiratory Tract Infection
  • Urinary Tract Infection
  • Ear Infection
  • Sexually Transmitted Infection
  • Other Application

 

By Administration

  • Oral
  • Intravenous

 

Regional Coverage

 

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Korea
    • Australia
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

 

Competitive Analysis:

 

Eminent market players have been outlined in order to extract improved insights into the worldwide businesses. Our research reports offer all-inclusive information on various top most manufacturers that are operational across global regions. We provide company profiles which include detailed overview of the company, business information, business performance, crucial strategies implemented through the years.

 

Few of the Key Players Covered in Our Report:

 

  • BRISTOL-MYERS SQUIBB COMPANY
  • ABBVIE INC. (ALLERGAN PLC.)
  • HOFFMANN-LA ROCHE LTD.
  • Boston Scientific Corporation
  • GLAXOSMITHKLINE PLC
  • LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.)
  • PFIZER INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • SANOFI
  • NOVARTIS INTERNATIONAL AG (SANDOZ)

 

Impact of COVID19:

 

The COVID19 pandemic crippled the global economy, it resulted in a worldwide lockdown and this has majorly impacted numerous industries. Our industry experts are working round-the-clock to identify, accumulate and in-time deliver market analysis due to the effect of unprecedented decisions in COVID-19 repercussions on many businesses. The full version of this report will comprise the overall impact of the pandemic, and predicted alteration on the future outlook of the industry, by taking into the account the economic, political, technological and social parameters.

This research study involves broad usage of both secondary and primary data sources. The research process involves the identification of numerous factors which affect the industry, comprising the market environment, government policy, historical data, present trends in the market, competitive landscape, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges.



Market Estimation

Top-down and bottom-up approaches are used for validating the market size for companies, regional segments along with relevant market segmentations such as product type and application.
This report includes market estimations which are based on the marketed sale price of a product. Further breakdown of product segments, particular market share are formed based on the weightage assigned to every segment, which is derived of their usage rate and average price. The entire probable factors which effect the markets and influence them in a great way are included in this research report; and have been accounted for, studied in-depth and are confirmed through primary research. These are then studies to get the final qualitative and quantitative data. Any of the factors such as the outcome of inflation, economic downfall, and any kind of policy and regulatory alterations and/or other such factors are not accounted for in the market forecast. All of this data is amalgamated and included with thorough inputs and analysis from Gravitas Market Insights is curated in this report.



Along with the previously mentioned approaches, various data triangulation methods, in order to conduct market estimations and market forecasting for the complete market segments are detailed in this report. Key Companies present in the said market are also acknowledged via in-depth secondary research and primary research.

Section 1: Executive Summary


1.1. Cephalosporin Market Industry 360° outline, Year 2016 – 2028
1.2. Business Model Trends
1.3. Growth Trends
1.4. End-User/Generation Trends
1.5. Regional Trends


Section 2: Market Dynamics - Cephalosporin Market Industry Insights


2.1. Growth Drivers
2.2. Opportunities
2.3. Industry challenges
2.4. SWOT Analysis
2.5. Porter’s Analysis
2.6. Worldwide Industry Landscape, Year 2016 – 2028
2.7. Industry Segmentation
2.8. Technology & Invention landscape
2.9. Regional Landscape
2.9.1. North America
2.9.2. Europe
2.9.3. Asia-Pacific
2.9.4. South America
2.9.5. Middle East & Africa
2.10. Competitive Environment


Section 3: Global Cephalosporin Market, By Type


3.1. Segmentation Analysis, By Type, 2016-2028
3.2. Market Share Segmentation Analysis, By Type, 2016-2028
3.3. Generic
3.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.4. Branded
3.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 4: Global Cephalosporin Market, By Generation


4.1. Segmentation Analysis, By Generation, 2016-2028
4.2. Market Share Segmentation Analysis, By Generation, 2016-2028
4.3. First-generation Cephalosporin
4.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.4. Second-generation Cephalosporin
4.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.5. Third-generation Cephalosporin
4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.6. Fourth-generation Cephalosporin
4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.7. Fifth-generation Cephalosporin
4.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 5: Global Cephalosporin Market, By Application


5.1. Segmentation Analysis, By Application, 2016-2028
5.2. Market Share Segmentation Analysis, By Application, 2016-2028
5.3. Skin Infection
5.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.4. Respiratory Tract Infection
5.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.5. Urinary Tract Infection
5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.6. Ear Infection
5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.7. Sexually Transmitted Infection
5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.8. Other Application
5.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 6: Global Cephalosporin Market, By Administration


6.1. Segmentation Analysis, By Administration, 2016-2028
6.2. Market Share Segmentation Analysis, By Administration, 2016-2028
6.3. Oral
6.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4. Intravenous
6.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 7: Global Cephalosporin Market, Regional Analysis


7.1. Global Cephalosporin Market, Regional Analysis


7.2. North America, Country level Analysis
7.2.1. North America Cephalosporin Market estimates and forecast with Growth rate analysis, By Type, 2016 – 2028
7.2.2. North America Cephalosporin Market estimates and forecast with Growth rate analysis, By Generation, 2016 – 2028
7.2.3. North America Cephalosporin Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.2.4. North America Cephalosporin Market estimates and forecast with Growth rate analysis, By Administration, 2016 – 2028
7.2.5. United States
7.2.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.2.6. Canada
7.2.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.2.7. Mexico
7.2.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.3. Europe Country level Analysis
7.3.1. Europe Cephalosporin Market estimates and forecast with Growth rate analysis, By Type, 2016 – 2028
7.3.2. Europe Cephalosporin Market estimates and forecast with Growth rate analysis, By Generation, 2016 – 2028
7.3.3. Europe Cephalosporin Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.3.4. Europe Cephalosporin Market estimates and forecast with Growth rate analysis, By Administration, 2016 – 2028
7.3.5. UK
7.3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.6. Germany
7.3.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.7. France
7.3.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.8. Italy
7.3.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.9. Spain
7.3.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.10. Russia
7.3.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.3.11. Rest of Europe
7.3.11.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.4. Asia-Pacific Country level Analysis
7.4.1. Asia-Pacific Cephalosporin Market estimates and forecast with Growth rate analysis, By Type, 2016 – 2028
7.4.2. Asia-Pacific Cephalosporin Market estimates and forecast with Growth rate analysis, By Generation, 2016 – 2028
7.4.3. Asia-Pacific Cephalosporin Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.4.4. Asia-Pacific Cephalosporin Market estimates and forecast with Growth rate analysis, By Administration, 2016 – 2028
7.4.5. China
7.4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.6. India
7.4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.7. Japan
7.4.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.8. Korea
7.4.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.9. Australia
7.4.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.10. Southeast Asia
7.4.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.4.11. Rest of Asia-Pacific
7.4.11.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.5. South America Country level Analysis
7.5.1. South America Cephalosporin Market estimates and forecast with Growth rate analysis, By Type, 2016 – 2028
7.5.2. South America Cephalosporin Market estimates and forecast with Growth rate analysis, By Generation, 2016 – 2028
7.5.3. South America Cephalosporin Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.5.4. South America Cephalosporin Market estimates and forecast with Growth rate analysis, By Administration, 2016 – 2028
7.5.5. Brazil
7.5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.5.6. Argentina
7.5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.5.7. Colombia
7.5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.5.8. Rest of South America
7.5.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


7.6. Middle East & Africa Country level Analysis
7.6.1. MEA Cephalosporin Market estimates and forecast with Growth rate analysis, By Type, 2016 – 2028
7.6.2. MEA Cephalosporin Market estimates and forecast with Growth rate analysis, By Generation, 2016 – 2028
7.6.3. MEA Cephalosporin Market estimates and forecast with Growth rate analysis, By Application, 2016 – 2028
7.6.4. MEA Cephalosporin Market estimates and forecast with Growth rate analysis, By Administration, 2016 – 2028
7.6.5. GCC
7.6.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.6.6. South Africa
7.6.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
7.6.7. Rest of Middle East & Africa
7.6.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028


Section 8: Company Profile - Cephalosporin Market


8.1. BRISTOL-MYERS SQUIBB COMPANY
8.1.1. Business Overview
8.1.2. Product & Service Offering
8.1.3. Overall Revenue
8.1.4. Strategic Outlook


8.2. ABBVIE INC. (ALLERGAN PLC.)
8.2.1. Business Overview
8.2.2. Product & Service Offering
8.2.3. Overall Revenue
8.2.4. Strategic Outlook


8.3. HOFFMANN-LA ROCHE LTD.
8.3.1. Business Overview
8.3.2. Product & Service Offering
8.3.3. Overall Revenue
8.3.4. Strategic Outlook


8.4. Boston Scientific Corporation
8.4.1. Business Overview
8.4.2. Product & Service Offering
8.4.3. Overall Revenue
8.4.4. Strategic Outlook


8.5. GLAXOSMITHKLINE PLC
8.5.1. Business Overview
8.5.2. Product & Service Offering
8.5.3. Overall Revenue
8.5.4. Strategic Outlook


8.6. LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.)
8.6.1. Business Overview
8.6.2. Product & Service Offering
8.6.3. Overall Revenue
8.6.4. Strategic Outlook


8.7. PFIZER INC.
8.7.1. Business Overview
8.7.2. Product & Service Offering
8.7.3. Overall Revenue
8.7.4. Strategic Outlook


8.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8.1. Business Overview
8.8.2. Product & Service Offering
8.8.3. Overall Revenue
8.8.4. Strategic Outlook


8.9. SANOFI
8.9.1. Business Overview
8.9.2. Product & Service Offering
8.9.3. Overall Revenue
8.9.4. Strategic Outlook


8.10. NOVARTIS INTERNATIONAL AG (SANDOZ)
8.10.1. Business Overview
8.10.2. Product & Service Offering 
8.10.3. Overall Revenue
8.10.4. Strategic Outlook

 

*Market size and forecast will be provided from 2016-2028, and forecast period would be 2021-2028
*Details on financial performance and strategic moves and developments may not be captured for unlisted companies
*List of companies profiled in this TOC is tentative and may change after detailed analysis